VRDN

Over the past six months, Viridian Therapeutics' stock has been impacted by several events: the FDA approval of Lumvoa for thyroid eye disease on June 26, 2026, caused VRDN stock to jump 6% after-hours, marking a significant transition for the company. In May 2026, Viridian completed convertible debt and equity financing, raising gross proceeds of $394 million. As of October 1, 2026, the stock decreased by 17.54% in the past month and by 8.6% over the last year, though it experienced a notable daily increase of +33.4% on May 5, 2026. On August 20, 2026, the company's legal chief sold 14,212 shares. Viridian Therapeutics also participated in the Wells Fargo 21st Annual Healthcare Conference on September 2, 2026.